FROM PAGE B1

hope every CF patient gets to experience this very, very soon. For most of my life, this medicine was not an option for me. Finally, there is effective, affordable treatment.”

Apart from Slovakia, patients from five countries, including South Africa, Qatar, the United States, the United Kingdom and Bangladesh, were among those who received the first doses of Triko last week.

Rabbur Reza, chief operating officer of Beximco Pharmaceuticals, said the drugmaker aims to address major gaps in access to essential medicines.

“At Beximco Pharma, we have always sought to address the unmet medical needs of patients, particularly in therapy areas characterised by severely limited access,” he said.

“We are deeply proud to be part of this meaningful initiative,” Reza added. “We believe that access to this life-saving treatment will have a truly transformative impact on the thousands of patients living with cystic fibrosis who are currently deprived of treatment due to the significant cost burden.”